Effects and determinants of tuberculosis drug stockouts in South Africa.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
03 Apr 2019
Historique:
received: 11 06 2018
accepted: 25 02 2019
entrez: 5 4 2019
pubmed: 5 4 2019
medline: 21 5 2019
Statut: epublish

Résumé

The frequent occurrence of medicine stockouts represents a significant obstacle to tuberculosis control in South Africa. Stockouts can lead to treatment alterations or interruptions, which can impact treatment outcomes. This study investigates the determinants and effects of TB drug stockouts and whether poorer districts are disproportionately affected. TB stockout data, health system indicators and TB treatment outcomes at the district level were extracted from the District Health Barometer for the years 2011, 2012 and 2013. Poverty terciles were constructed using the Census 2011 data to investigate whether stockouts and poor treatment outcomes were more prevalent in more impoverished districts. Fixed-effects regressions were used to estimate the effects of TB stockouts on TB treatment outcomes. TB stockouts occurred in all provinces but varied across provinces and years. Regression analysis showed a significant association between district per capita income and stockouts: a 10% rise in income was associated with an 8.50% decline in stockout proportions. In terms of consequences, after controlling for unobserved time invariant heterogeneity between districts, a 10% rise in TB drug stockouts was found to lower the cure rate by 2.10% (p < 0.01) and the success rate by 1.42% (p < 0.01). These effects were found to be larger in poorer districts. The unequal spread of TB drug stockouts adds to the socioeconomic inequality in TB outcomes. Not only are stockouts more prevalent in poorer parts of South Africa, they also have a more severe impact on TB treatment outcomes in poorer districts. This suggests that efforts to cut back TB drug stockouts would not only improve TB treatment outcomes on average, they are also likely to improve equity because a disproportionate share of this burden is currently borne by the poorer districts.

Sections du résumé

BACKGROUND BACKGROUND
The frequent occurrence of medicine stockouts represents a significant obstacle to tuberculosis control in South Africa. Stockouts can lead to treatment alterations or interruptions, which can impact treatment outcomes. This study investigates the determinants and effects of TB drug stockouts and whether poorer districts are disproportionately affected.
METHODS METHODS
TB stockout data, health system indicators and TB treatment outcomes at the district level were extracted from the District Health Barometer for the years 2011, 2012 and 2013. Poverty terciles were constructed using the Census 2011 data to investigate whether stockouts and poor treatment outcomes were more prevalent in more impoverished districts. Fixed-effects regressions were used to estimate the effects of TB stockouts on TB treatment outcomes.
RESULTS RESULTS
TB stockouts occurred in all provinces but varied across provinces and years. Regression analysis showed a significant association between district per capita income and stockouts: a 10% rise in income was associated with an 8.50% decline in stockout proportions. In terms of consequences, after controlling for unobserved time invariant heterogeneity between districts, a 10% rise in TB drug stockouts was found to lower the cure rate by 2.10% (p < 0.01) and the success rate by 1.42% (p < 0.01). These effects were found to be larger in poorer districts.
CONCLUSIONS CONCLUSIONS
The unequal spread of TB drug stockouts adds to the socioeconomic inequality in TB outcomes. Not only are stockouts more prevalent in poorer parts of South Africa, they also have a more severe impact on TB treatment outcomes in poorer districts. This suggests that efforts to cut back TB drug stockouts would not only improve TB treatment outcomes on average, they are also likely to improve equity because a disproportionate share of this burden is currently borne by the poorer districts.

Identifiants

pubmed: 30943967
doi: 10.1186/s12913-019-3972-x
pii: 10.1186/s12913-019-3972-x
pmc: PMC6448237
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213

Références

Int J Clin Pharm. 2016 Oct;38(5):1133-41
pubmed: 27383246
N Engl J Med. 2010 Aug 26;363(9):806-7
pubmed: 20554977
S Afr Med J. 2013 Sep;103(9):600-2
pubmed: 24344422
Bull World Health Organ. 2007 Sep;85(9):703-11
pubmed: 18026627
PLoS One. 2014 Dec 11;9(12):e114762
pubmed: 25500832
J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-107
pubmed: 17624830
Health Syst Reform. 2015 Feb 17;1(2):142-154
pubmed: 31546312
N Engl J Med. 2012 Dec 27;367(26):2461-3
pubmed: 23268661
Trop Med Int Health. 2011 Oct;16(10):1297-313
pubmed: 21718394
Int J Tuberc Lung Dis. 2001 Nov;5(11):1000-5
pubmed: 11716335
Mayo Clin Proc. 2014 Mar;89(3):361-73
pubmed: 24582195
Healthc Policy. 2012 May;7(4):10-7
pubmed: 23634158
Malawi Med J. 2016 Mar;28(1):6-9
pubmed: 27217910
PLoS One. 2010 Oct 15;5(10):e13414
pubmed: 20976211
J Health Popul Nutr. 2002 Dec;20(4):289-96
pubmed: 12659408
J R Soc Med. 2001 Jun;94(6):261-3
pubmed: 11387411

Auteurs

L E M Koomen (LEM)

Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, PA, 3062, The Netherlands.

R Burger (R)

Department of Economics, Stellenbosch University, Stellenbosch, South Africa.

E K A van Doorslaer (EKA)

Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, PA, 3062, The Netherlands. vandoorslaer@ese.eur.nl.
Department of Economics, Stellenbosch University, Stellenbosch, South Africa. vandoorslaer@ese.eur.nl.
Erasmus School of Economics, Erasmus University Rotterdam, Burgemeester Oudlaan 50, Rotterdam, PA, 3062, The Netherlands. vandoorslaer@ese.eur.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH